174 related articles for article (PubMed ID: 32888373)
1. Successful and rapid clearance of severe, treatment-resistant atopic dermatitis with dupilumab in a 3-year-old.
Dakin H; Haas C
Dermatol Ther; 2020 Nov; 33(6):e14282. PubMed ID: 32888373
[No Abstract] [Full Text] [Related]
2. Use of dupilumab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis.
Siegfried EC; Igelman S; Jaworski JC; Antaya RJ; Cordoro KM; Eichenfield LF; Levy ML; Paller AS
Pediatr Dermatol; 2019 Jan; 36(1):172-176. PubMed ID: 30675938
[No Abstract] [Full Text] [Related]
3. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
[No Abstract] [Full Text] [Related]
4. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
Achten R; Thijs J; van Luijk C; Knol E; Delemarre E; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
Clin Exp Allergy; 2023 Feb; 53(2):239-243. PubMed ID: 36550628
[No Abstract] [Full Text] [Related]
5. A rare presentation of herpes simplex virus encephalitis occurring in a pediatric patient on dupilumab for atopic dermatitis.
Rao M; Grove D; Haggstrom A
Pediatr Dermatol; 2022 Mar; 39(2):288-290. PubMed ID: 35243667
[TBL] [Abstract][Full Text] [Related]
6. Serum IL-22 binding protein as a marker for atopic dermatitis activity and response to dupilumab treatment.
Varandas C; Pereira-Santos MC; Neto M; Sousa AE; Lopes A; Silva SL
Clin Exp Allergy; 2022 Jun; 52(6):820-823. PubMed ID: 35416344
[No Abstract] [Full Text] [Related]
7. Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab.
Wang M; Zheng Q; Tang S; Shen F; Jiang W
Acta Derm Venereol; 2022 Jun; 102():adv00744. PubMed ID: 35670327
[No Abstract] [Full Text] [Related]
8. Dupilumab provides rapid improvement for morphologic variants of paediatric atopic dermatitis: A case series.
Kim JW; Kim M; Ahn GS; Na JI
Indian J Dermatol Venereol Leprol; 2022; 88(6):834-839. PubMed ID: 36331828
[No Abstract] [Full Text] [Related]
9. Omalizumab for treatment of refractory severe atopic dermatitis. A pediatric perspective.
Iannelli M; Caminiti L; Vaccaro M; Marafioti I; Spinuzza A; Panasiti I; Barbalace A; Crisafulli G; Pajno GB
Dermatol Ther; 2020 Jul; 33(4):e13519. PubMed ID: 32378300
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab (Dupixent) for moderate to severe atopic dermatitis.
Med Lett Drugs Ther; 2017 Apr; 59(1519):64-66. PubMed ID: 28419072
[No Abstract] [Full Text] [Related]
11. [Psoriasis in dupilumab-treated atopic dermatitis].
Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
[TBL] [Abstract][Full Text] [Related]
12. Successful dose reduction of dupilumab in atopic dermatitis.
Ardern-Jones MR; Buchanan EE; Njungu S; O'Driscoll D
Br J Dermatol; 2023 Apr; 188(5):678-679. PubMed ID: 36662536
[No Abstract] [Full Text] [Related]
13. Dupilumab for Atopic Dermatitis, a Possible Risk Factor of Juvenile Ischemic Stroke: A Case Report.
Iwase R; Ishiguro T; Fujita K; Ishibashi S; Yokota T
J Stroke Cerebrovasc Dis; 2020 Jun; 29(6):104763. PubMed ID: 32265139
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
Blakely K; Gooderham M; Papp K
Skin Therapy Lett; 2016 Mar; 21(2):1-5. PubMed ID: 27223113
[TBL] [Abstract][Full Text] [Related]
15. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
Lor M; Villa N; Holland V
Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus.
Tavakolpour S
Dermatol Ther; 2016 Sep; 29(5):299. PubMed ID: 26800435
[No Abstract] [Full Text] [Related]
17. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
18. Serum biomarker analysis to identify subtypes of atopic dermatitis in China and to help with predicting the effectiveness of treatment with dupilumab.
Br J Dermatol; 2023 Apr; 188(5):e37. PubMed ID: 37078765
[No Abstract] [Full Text] [Related]
19. Angioedema: A potential complication of dupilumab in atopic dermatitis.
Fritz AL; Lacy FA; Morrell DS
Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
